Clinical Trials

Phase 3 Active not recruiting

Penile Squamous Cell Carcinoma (PSCC)

NCT03271372 2026-04-13

ADAM

101 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Merkel Cell

NCT03964532 2026-04-09

TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

24 enrolled

Breast Neoplasms

NCT04291885 2026-04-09

I-MAT

122 enrolled

DermatologicEndocrineNET

Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04841148 2026-04-09

PALAVY

Phase 2 Recruiting

96 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05327686 2026-04-08

SAMURAI

Phase 2 Recruiting

240 enrolled

Carcinoma, Renal Cell

NCT04792073 2026-04-07

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

18 enrolled

Neoplasm Metastasis, Carcinoma, Merkel Cell

NCT04360941 2026-04-06

PAveMenT

Phase 1 Recruiting

45 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04261855 2026-03-27

GoTHAM

19 enrolled

DermatologicEndocrineNET

Carcinoma, Carcinoma, Merkel Cell, Neuroendocrine Tumors

NCT04387084 2026-03-23

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Phase 1 Active not recruiting

10 enrolled

Phase 3 Active not recruiting

Skin Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT03573648 2026-03-19

ImmunoADAPT

33 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT04902040 2026-03-18

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Phase 1/2 Terminated

19 enrolled 11 charts

GenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

NCT04004442 2026-03-13

COAXIN

19 enrolled

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07460245 2026-03-10

AVESEC

144 enrolled

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

NCT03719768 2026-03-02

Avelumab With Radiotherapy in Patients With Leptomeningeal Disease

Phase 1 Completed

16 enrolled

CNS

Brain Neoplasms, Meningeal Neoplasms, Meningeal Carcinomatosis

NCT03006848 2026-02-23

A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma

Phase 2 Completed

19 enrolled 11 charts

Sarcoma

Osteosarcoma

NCT03252938 2026-02-19

INSIGHT

83 enrolled

GenitourinaryGynecologic

Carcinoma, Transitional Cell, Peritoneal Neoplasms

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Phase EARLY_PHASE1 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT05358938 2026-02-06

Exercise to Boost Response to Checkpoint Blockade Immunotherapy

22 enrolled

Melanoma, Motor Activity, Skin Neoplasms, Carcinoma, Merkel Cell

NCT03944941 2026-02-05

Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

60 enrolled

Skin Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

9 enrolled